Research programme: antibody therapeutics - Adimab/Cascadian Therapeutics
Latest Information Update: 09 Jun 2016
At a glance
- Originator Adimab
- Class Bispecific antibodies; Monoclonal antibodies
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 08 Jun 2016 Oncothyreon is now called Cascadian Therapeutics
- 09 Jan 2015 Early research in Cancer in USA (unspecified route)